NASDAQ:DMRA
Damora Therapeutics, Inc.
Damora Therapeutics, Inc. reported net income of −$209.8M in fiscal 2025. The diluted share count rose 17.8%.Summary generated from Damora Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−163.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+17.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −52 | −61 | −40 | −22 | −211 |
| Net income | −52 | −62 | −38 | −21 | −210 |
| Free cash flow | −53 | −43 | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 28, 2026 - 4Insider transaction report
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KEntry into a material agreement
Jul 20, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KDirector or officer change
May 4, 2026 - DEF 14AProxy statement
Apr 29, 2026